Sign In
Buy LLY
$1,116.11
-5.06 (-0.451%)
At Close: Aug 04, 2026
Lilly gains license for Ascidian's gene-editing tech to develop kidney disease drugs
07:00am, Wednesday, 03'rd Jun 2026
Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly , worth up to $1.9 billion, to develop new therapies for rare i
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out
03:00am, Wednesday, 03'rd Jun 2026
Eli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate. It could compete with CRISPR Therapeutics, a gene editing-focused biotech.
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
09:30am, Tuesday, 02'nd Jun 2026
Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL
Top 25 High-Growth Dividend Stocks For June 2026
05:14am, Tuesday, 02'nd Jun 2026
The June 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading ~30% below intrinsic value, with a 1.50% average yield and 17.61% five-year dividend growth. I estimate a compel
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish
01:43pm, Monday, 01'st Jun 2026
David Ricks was addressing the pharmaceutical titan's latest hot product.
Eli Lilly Growing at 55% as a Trillion-Dollar Company: ‘These Are NVIDIA-Like Growth Numbers'
11:35am, Monday, 01'st Jun 2026
Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano.
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
07:04am, Monday, 01'st Jun 2026
U.S. drugmaker Eli Lilly has entered into an agreement to collaborate on and possibly licence experimental medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring
Invesco Summit Fund Q1 2026 Portfolio Update
05:12am, Sunday, 31'st May 2026
At quarter end, Invesco Summit Fund's largest overweights were in industrials, energy and communication services. Within industrials and energy, AI related energy demand has continued to drive spendin
Stock Split Watch: Is Eli Lilly Next?
03:50am, Saturday, 30'th May 2026
Eli Lilly stock has climbed in the triple-digits in recent years and just topped $1,000. The company is firing on all cylinders in the high-growth weight loss drug market.
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
11:51am, Friday, 29'th May 2026
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
Lilly Reopens Zepbound Access For 10 Million US Patients
09:22am, Friday, 29'th May 2026
Eli Lilly (LLY) is getting a major access win in the obesity drug market after CVS Health reversed its earlier restriction on Zepbound across certain drug plans
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
05:24pm, Thursday, 28'th May 2026
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly Expands Into Infectious Diseases, Retatrutide Adds Another Phase 3 Win
09:45am, Thursday, 28'th May 2026
Eli Lilly continues strong execution, exceeding revenue expectations and expanding its pipeline with strategic, low-risk acquisitions in infectious diseases and other areas. LLY's infectious disease d
